“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical trials. We report the outcomes of 36 patients treated at Mayo Clinic. Our cohort received a me...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaxman, I., Abeykoon, J., Dispenzieri, A., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Reeder, C., Sher, T., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Go, R., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Kristen, McCullough, Kapoor, P., Gertz, M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651684/
https://www.ncbi.nlm.nih.gov/pubmed/34876555
http://dx.doi.org/10.1038/s41408-021-00592-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651684/
https://www.ncbi.nlm.nih.gov/pubmed/34876555
http://dx.doi.org/10.1038/s41408-021-00592-3

Ejemplares similares